Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Iovance Biotherapeutics, Inc. (IOVA) had Cost of Goods Sold of $49.74M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$49.32M |
|
$-116.16M |
|
|
Cost of Goods Sold |
$49.74M |
$-0.42M |
|
$170.54M |
|
$-121.22M |
|
$3.22M |
|
$-118.00M |
|
$-118.00M |
|
$-116.16M |
|
$-116.16M |
|
$-116.16M |
|
$-116.16M |
|
$-121.22M |
|
$-112.30M |
|
322.87M |
|
322.87M |
|
$-0.36 |
|
$-0.36 |
|
| Balance Sheet Financials | |
$512.65M |
|
$111.58M |
|
$454.09M |
|
$966.74M |
|
$122.69M |
|
-- |
|
$76.18M |
|
$198.88M |
|
$767.86M |
|
$482.51M |
|
$767.87M |
|
333.93M |
|
| Cash Flow Statement Financials | |
$-103.69M |
|
$15.87M |
|
$143.31M |
|
$122.05M |
|
$178.05M |
|
$56.00M |
|
$22.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.18 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-0.85% |
|
-245.76% |
|
-245.76% |
|
-- |
|
-239.24% |
|
-235.51% |
|
$-109.91M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
0.76 |
|
0.70 |
|
129.44 |
|
-15.13% |
|
-24.07% |
|
-12.02% |
|
-15.13% |
|
$2.30 |
|
$-0.34 |
|
$-0.32 |
|